Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of “Buy” by Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have earned a consensus recommendation of “Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $136.50.

A number of research firms have recently issued reports on PCVX. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Vaxcyte in a research note on Tuesday, April 8th. Guggenheim reissued a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Cantor Fitzgerald started coverage on Vaxcyte in a research note on Tuesday, April 22nd. They set an “overweight” rating for the company. Evercore ISI raised shares of Vaxcyte to a “strong-buy” rating in a research report on Monday, March 31st. Finally, The Goldman Sachs Group lowered their price objective on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st.

Institutional Investors Weigh In On Vaxcyte

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its position in shares of Vaxcyte by 5.5% in the first quarter. Rhumbline Advisers now owns 181,230 shares of the company’s stock worth $6,843,000 after purchasing an additional 9,416 shares during the period. Strs Ohio purchased a new position in shares of Vaxcyte during the 1st quarter valued at $627,000. Intech Investment Management LLC increased its stake in Vaxcyte by 44.3% in the 1st quarter. Intech Investment Management LLC now owns 89,212 shares of the company’s stock worth $3,369,000 after buying an additional 27,384 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Vaxcyte by 8.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock worth $19,409,000 after buying an additional 41,034 shares in the last quarter. Finally, Caxton Associates LLP bought a new stake in Vaxcyte during the first quarter valued at about $226,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX opened at $33.84 on Thursday. The firm has a market cap of $4.37 billion, a price-to-earnings ratio of -7.36 and a beta of 1.20. The business has a 50-day simple moving average of $32.22 and a two-hundred day simple moving average of $65.79. Vaxcyte has a fifty-two week low of $27.66 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the previous year, the firm earned ($0.85) EPS. As a group, research analysts predict that Vaxcyte will post -4.21 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.